CD274 and neoplasm: Although current clinical trials have shown limited efficacy of PD-1/PD-L1 inhibitors in LMS, with objective response rates below 10% and low PD-L1 expression across most tumors, our findings suggest that high-stemness LMS cells exhibit a more complex and active tumor immune microenvironment.